We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+16.89%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$1.82B
AUM Growth
+$296M
Cap. Flow
+$80.3M
Cap. Flow %
4.42%
Top 10 Hldgs %
36.79%
Holding
155
New
17
Increased
81
Reduced
30
Closed
18

Top Buys

Rank Stock Value
1
EVH icon
Evolent Health
EVH
+$21.6M
2
HUM icon
Humana
HUM
+$21.3M
3
TDOC icon
Teladoc Health
TDOC
+$18.3M
4
BMY icon
Bristol-Myers Squibb
BMY
+$10.4M
5
AVDR
Avedro, Inc Common Stock
AVDR
+$9.38M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$56M
2
AMGN icon
Amgen
AMGN
+$5.81M
3
BIIB icon
Biogen
BIIB
+$5.29M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$5.16M
5
MGNX icon
MacroGenics
MGNX
+$4.78M

Sector Composition

Rank Sector Weight
1 Healthcare 91.35%
2 Industrials 1.12%
3 Technology 0.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDSO
76
DELISTED
Medidata Solutions, Inc.
MDSO
$5.16M 0.28%
70,474
+21,263
+43% +$1.53M
GILD icon
77
Gilead Sciences
GILD
$166B
$5.06M 0.28%
77,800
-45,200
-37% -$3M
VCRA
78
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$5M 0.28%
158,214
+125,264
+380% +$4.44M
STIM icon
79
Neuronetics
STIM
$130M
$4.5M 0.25%
295,337
+129,937
+79% +$2.15M
HOLX
80
DELISTED
Hologic
HOLX
$4.36M 0.24%
90,000
– –
CHRS icon
81
Coherus Oncology
CHRS
$214M
$4.33M 0.24%
317,135
-41,800
-12% -$558K
MTLS
82
Materialise
MTLS
$379M
$4.22M 0.23%
268,409
+53,217
+25% +$935K
HZNP
83
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$4.2M 0.23%
158,800
-9,700
-6% -$230K
INCY icon
84
Incyte
INCY
$23.2B
$4.17M 0.23%
48,500
-10,150
-17% -$826K
AMED
85
DELISTED
Amedisys
AMED
$4.15M 0.23%
33,656
+8,452
+34% +$1.06M
BLUE
86
DELISTED
bluebird bio
BLUE
$3.63M 0.2%
1,783
+787
+79% +$1.39M
PEN icon
87
Penumbra
PEN
$12.5B
$3.48M 0.19%
23,637
-413
-2% -$59K
VTRS icon
88
Viatris
VTRS
$20B
$3.46M 0.19%
122,000
-74,950
-38% -$2.19M
SGEN
89
DELISTED
Seagen Inc. Common Stock
SGEN
$3.35M 0.18%
45,800
+10,800
+31% +$768K
SWAV
90
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$3.35M 0.18%
+100,000
New +$3.32M
EXEL icon
91
Exelixis
EXEL
$14.2B
$3.34M 0.18%
140,500
+46,500
+49% +$1.06M
MASI
92
DELISTED
Masimo
MASI
$3.15M 0.17%
22,780
– –
CVS icon
93
CVS Health
CVS
$138B
$3.11M 0.17%
57,627
+31,802
+123% +$1.96M
HSIC icon
94
Henry Schein
HSIC
$9.83B
$3.04M 0.17%
50,662
-14,832
-23% -$895K
JNJ icon
95
Johnson & Johnson
JNJ
$606B
$2.8M 0.15%
20,000
– –
ACAD icon
96
Acadia Pharmaceuticals
ACAD
$4.34B
$2.79M 0.15%
103,800
+8,000
+8% +$187K
AMGN icon
97
Amgen
AMGN
$198B
$2.75M 0.15%
14,500
-30,450
-68% -$5.81M
KYNB
98
Kyntra Bio
KYNB
$29.3M
$2.65M 0.15%
1,952
+672
+53% +$911K
SAGE
99
DELISTED
Sage Therapeutics
SAGE
$2.59M 0.14%
16,300
+5,700
+54% +$825K
ARGX icon
100
argenx
ARGX
$53.8B
$2.48M 0.14%
19,900
+7,300
+58% +$858K
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2019 Portfolio in Review

As of Q1 2019, Bellevue Group held 155 positions worth $1.82B, up 19% from $1.52B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Bellevue Group deployed $80.3M of net new capital in Q1 2019, opening 17 new positions and adding to 81 existing holdings. Its largest new stake was Avedro, Inc Common Stock: 750,000 shares worth $9.2M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 88% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Celgene Corp, an estimated $56M trimmed.

  • Bellevue Group's largest Q1 2019 buy was Avedro, Inc Common Stock: 750,000 shares worth $9.2M.
  • Bellevue Group added most to Evolent Health in Q1 2019, an estimated $21.6M increase.
  • Bellevue Group's biggest Q1 2019 reduction was Celgene Corp, cutting an estimated $56M.
  • Bellevue Group fully exited BioMarin Pharmaceuticals in Q1 2019, selling an estimated $3.91M.
  • Bellevue Group's ten largest holdings make up 37% of its $1.82B portfolio in Q1 2019.
  • Bellevue Group opened 17 new positions and closed 18 in Q1 2019.
  • Bellevue Group's portfolio value rose 19% quarter-over-quarter to $1.82B.

Based on Bellevue Group's 13F filing for Q1 2019, filed 15 May 2019.